Joseph Panarelli, MD
Ophthalmology · New York, NYNPI 1194975177
Payments from drug & device makers
Across 549 payments — averaging $1282.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$453K
- Alcon$117K
- Bausch & Lomb Americas Inc.$39K
- Aerie Pharmaceuticals, Inc.$38K
- Glaukos Corporation$23K
- Nova Eye, Inc.$18K
- plus $16K from 7 others
What the payments were for
- Consulting fees$213,77840%
- Speaking & faculty fees$273,91251%
- Travel & lodging$40,6878%
- Food & beverage$12,3982%
- Education$910%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 331 | $453,451 |
| Alcon | 83 | $116,636 |
| Bausch & Lomb Americas Inc. | 34 | $38,806 |
| Aerie Pharmaceuticals, Inc. | 39 | $38,124 |
| Glaukos Corporation | 33 | $23,133 |
| Nova Eye, Inc. | 6 | $17,659 |
| Carl Zeiss Meditec, Inc. | 5 | $8,824 |
| Thea Pharma Inc. | 5 | $4,978 |
| NEW World Medical,inc. | 7 | $1,346 |
| Ivantis, Inc | 1 | $803 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $133 |
| Ocular Therapeutix, Inc. | 3 | $99 |
| Harrow Eye, LLC | 1 | $33 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rhopressa$141,010
- Rocklatan$132,644
- XEN GLAUCOMA TREATMENT SYSTEM$92,874
- DURYSTA$67,732
- LUMIGAN$48,158
- VYZULTA$38,379
- SIMBRINZA$34,409
- XEN$31,662
- COMBIGAN$24,964
- Travoprost Intraocular Implant - iDose$9,247
- CIRRUS HD-OCT$8,820
- FORUM$8,820
- Humphrey HFA$6,220
- CLARUS$6,220
- FORUM Glaucoma Workplace$5,200
- IYUZEH$4,875
- iStent inject Trabecular Micro-Bypass Stent System$4,528
- ALPHAGAN P$4,388
- iStent Trabecular Micro-Bypass Stent System$3,131
- RESTASIS$2,750
How this compares
$704,027 in reported general payments places this provider in the 95th percentile of 1,587 ophthalmology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 315 | $178,001 |
| CombiganBrimonidine Tartrate/Timolol | 243 | $113,541 |
| RocklatanNetarsudil Mesylat/Latanoprost | 78 | $45,383 |
| Alphagan PBrimonidine Tartrate | 96 | $44,980 |
| VyzultaLatanoprostene Bunod | 75 | $40,045 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 108 | $35,268 |
| RhopressaNetarsudil Mesylate | 39 | $31,408 |
| RestasisCyclosporine | 23 | $27,624 |
| AzoptBrinzolamide | 39 | $20,664 |
| ProlensaBromfenac Sodium | 36 | $18,018 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 79 | $14,683 |
| Difluprednate | 128 | $12,960 |
| Prednisolone Acetate | 283 | $12,760 |
| Brinzolamide | 82 | $12,387 |
| BesivanceBesifloxacin Hcl | 57 | $12,297 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Alphagan P, Restasis | $453,451 | $364,145677 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $38,124 | $76,791117 claims |
| AlconSimbrinza, Azopt | $116,636 | $55,932147 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Xiidra | $38,806 | $49,13786 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Besivance, Loteprednol Etabonate | $133 | $38,483133 claims |
| Thea Pharma Inc.Iyuzeh | $4,978 | $9,62923 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,587 ophthalmology providers in New York.
Other ophthalmology in New York
- Douglas JabsNew York$24.3M
- Nathan RadcliffeNew York$2.4M
- Richard SpaideNew York$1.7M
- Jason SlakterNew York$1.2M
- David ChuNew York$1.2M
- Sharon KehNew York$941K
- Joshua YoungNew York$814K
- Joshua KimNew York$677K
- Eric RosenbergNew York$526K
- Ashley BrissetteNew York$452K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.